Insider Trading Activity Blueprint Medicines Corporation (NASDAQ:BPMC) – CEO Sold 20,000 shares of Stock

ME Staff

7 years ago

Insider Trading Activity For Blueprint Medicines Corporation (NASDAQ:BPMC)

Jeffrey W Albers , CEO of Blueprint Medicines Corporation (NASDAQ:BPMC) reportedly Sold 20,000 shares of the company’s stock at an average price of 49.08 for a total transaction amount of $981,600.00 SEC Form

Insider Trading History For Blueprint Medicines Corporation (NASDAQ:BPMC)

On 11/3/2015 Christoph Lengauer, insider, sold 84,998 with an average share price of $21.05 per share and the total transaction amounting to $1,789,207.90.View SEC Filing

On 11/17/2015 Fmr Llc, Insider, sold 27,490 with an average share price of $20.60 per share and the total transaction amounting to $566,294.00.View SEC Filing

On 11/19/2015 Fmr Llc, Insider, sold 237,218 with an average share price of $19.76 per share and the total transaction amounting to $4,687,427.68.View SEC Filing

On 11/23/2015 Fmr Llc, Insider, sold 189,572 with an average share price of $20.15 per share and the total transaction amounting to $3,819,875.80.View SEC Filing

On 11/24/2015 Fmr Llc, Insider, sold 161,271 with an average share price of $20.14 per share and the total transaction amounting to $3,247,997.94.View SEC Filing

On 11/27/2015 Fmr Llc, Insider, sold 287,415 with an average share price of $21.48 per share and the total transaction amounting to $6,173,674.20.View SEC Filing

On 12/17/2015 Christoph Lengauer, insider, sold 31,119 with an average share price of $25.05 per share and the total transaction amounting to $779,530.95.View SEC Filing

Analyst Ratings For Blueprint Medicines Corporation (NASDAQ:BPMC)
These are 7 Buy Ratings .
The current consensus rating for Blueprint Medicines Corporation (NASDAQ:BPMC) is Buy (Score: 3.00) with a consensus target price of $48.46 , a potential (1.05% upside)

Analyst Ratings History For Blueprint Medicines Corporation (NASDAQ:BPMC)

On 3/9/2016 J P Morgan Chase & Co Lower Price Target of rating Market Outperform with a price target of $54.00 to $37.00
On 5/27/2016 Raymond James Financial, Inc. Initiated Coverage of rating Outperform with a price target of $23.00
On 2/15/2017 Morgan Stanley Initiated Coverage of rating Overweight with a price target of $45.00
On 3/13/2017 Goldman Sachs Group, Inc. (The) Upgraded rating Neutral to Buy with a price target of $52.00
On 3/22/2017 JMP Securities Initiated Coverage of rating Outperform with a price target of $37.00 to $46.00
On 5/4/2017 Jefferies Group LLC Boost Price Target of rating Buy with a price target of $42.00 to $52.00
On 6/6/2017 Wedbush Reiterated Rating Outperform with a price target of $55.00

Recent Trading Activity for Blueprint Medicines Corporation (NASDAQ:BPMC)
Shares of Blueprint Medicines Corporation closed the previous trading session at 47.95 down -1.35 -2.74% with 195,824 shares trading hands.